Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis (OA) (2003-12-31) (Q86243492)
Jump to navigation
Jump to search
clinical trial
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis (OA) (2003-12-31) |
clinical trial |
Statements
A 39-week, Double-blind, Active-controlled Extension to CCOX189A2361, a 13-week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel Trial of 2 Different Dose Regimens of Lumiracoxib (100 mg od and 200 mg od Initial Dose for Two Weeks Followed by 100 mg od) in Patients With Primary Knee Osteoarthritis, Using Celecoxib (200 mg od) as a Comparator (English)
0 references
December 2003
0 references
November 2004
0 references
1,312
0 references
18 year
0 references